Wogonoside alleviates hyperosmotic stress-induced inflammation and apoptosis in human corneal epithelial cells via PI3K/AKT signaling - Top-Institutions - MDSpire

Wogonoside alleviates hyperosmotic stress-induced inflammation and apoptosis in human corneal epithelial cells via PI3K/AKT signaling

  • By

  • Yuan Zhong

  • Jian Shi

  • Xi Long

  • Xiyuan Liu

  • Lihao Chen

  • Jun Peng

  • Qinghua Peng

  • May 4, 2026

  • 0 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    Bascom Palmer Eye Institute, University of Miami Health System
    Bascom Palmer Eye Institute, University of Miami Health System

    Miami, Florida

    Key Differentiators

    • Ophthalmology

  • #2

    Massachusetts Eye and Ear/Schepens Eye Research Institute, Harvard Medical School
    Massachusetts Eye and Ear/Schepens Eye Research Institute, Harvard Medical School

    Boston, Massachusetts

    Key Differentiators

    • Ophthalmology

  • #3

    Renmin Hospital of Wuhan University
    Renmin Hospital of Wuhan University

    Wuhan, Hubei

    Key Differentiators

    • Ophthalmology

  • #4

    Indiana University School of Medicine
    Indiana University School of Medicine

    Indianapolis, Indiana

    Key Differentiators

    • Ophthalmology

  • #5

    University of Pittsburgh School of Medicine
    University of Pittsburgh School of Medicine

    Pittsburgh, Pennsylvania

    Key Differentiators

    • Ophthalmology

Original Source(s)

Wogonoside alleviates hyperosmotic stress-induced inflammation and apoptosis in human corneal epithelial cells via PI3K/AKT signaling

  • by Yuan Zhong, Jian Shi, Xi Long, Xiyuan Liu, Lihao Chen, Jun Peng, Qinghua Peng

  • May 4, 2026

Related Content

Study Provides Real-World Evidence for Inflammatory DED

Carolina L. Mercado, MD, and colleagues presented data from the American Academy of Ophthalmology IRIS (Intelligent Research in Sight) Registry linked to pharmacy claims data sourced from the Komodo Health Research Dataset.

Japan Debuts Novel Dry Eye Therapy

Senju Pharmaceutical launches the first TRPV1 antagonist for dry eye in Japan

  • April 30, 2026

  • 3 min
Integrated management of dry eye–depression comorbidity: mechanistic insights and temporal therapeutic strategies